Get the Stockscreener App
3.34
1.18%
-0.04
After Hours:
3.34
Alvotech stock is traded at $3.34, with a volume of 197.52K.
It is down -1.18% in the last 24 hours and down -4.57% over the past month.
Alvotech is a biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients globally. Its purpose is to improve the health and quality of life of patients around the world by improving access to treatments for various diseases. The company's commercialized products incldue AVT02, AVT03, AVT04, AVT05, and AVT06. Its pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, and cancer. Geographically, the company generates the majority of revenue from Europe, and the rest from the USA and the rest of the world.
See More
Previous Close:
$3.38
Open:
$3.38
24h Volume:
197.52K
Relative Volume:
0.37
Market Cap:
$1.04B
Revenue:
$563.46M
Net Income/Loss:
$27.92M
P/E Ratio:
34.65
EPS:
0.0964
Net Cash Flow:
$-146.33M
1W Performance:
+0.91%
1M Performance:
-4.57%
6M Performance:
-35.02%
1Y Performance:
-66.40%
1-Day Range:
$3.31
$3.44
1-Week Range:
$3.20
$3.44
52-Week Range:
$3.03
$11.85
Alvotech Stock (ALVO) Company Profile
Compare ALVO vs TAK, HLN, TEVA, ZTS, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALVO
Alvotech
|
3.34 | 1.05B | 563.46M | 27.92M | -146.33M | 0.0964 |
TAK
Takeda Pharmaceutical Co Adr
|
16.25 | 52.07B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.29 | 41.28B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
34.07 | 39.78B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
81.32 | 33.57B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
568.43 | 24.02B | 3.17B | 1.29B | 1.01B | 27.09 |
Alvotech Stock (ALVO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-09-25 | Initiated | Barclays | Underweight |
| Nov-04-25 | Downgrade | Deutsche Bank | Buy → Hold |
| Oct-14-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-23-25 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-14-25 | Initiated | UBS | Buy |
| Jan-29-24 | Upgrade | Barclays | Equal Weight → Overweight |
| Oct-20-23 | Upgrade | Citigroup | Sell → Neutral |
| Sep-21-23 | Initiated | Barclays | Equal Weight |
| Sep-07-22 | Initiated | Morgan Stanley | Equal-Weight |
| Sep-06-22 | Downgrade | Citigroup | Buy → Sell |
| Jul-26-22 | Initiated | Citigroup | Buy |
View All
Alvotech Stock (ALVO) Latest News
Alvotech founder Robert Wessman threatens to quit Britain over ‘anti-wealth’ tax regime - Business Matters
Alvotech plans June FDA resubmissions, sees biosimilar approvals by year-end - MSN
Does Alvotech’s (ALVO) FDA Inspection Outcome Reframe Confidence in Its Biosimilar Strategy for 2026? - simplywall.st
Alvotech stock (LU2557688560): 2026 outlook reaffirmed after earnings call - AD HOC NEWS
Alvotech Earnings Call Balances Setbacks and Momentum - TipRanks
Earnings Preview: Alvotech to Report Financial Results on May 06 - 富途牛牛
Quant snapshot: Micron, Babcock & Wilcox lead strong buys as Fold Holdings, Alvotech lag - MSN
Alvotech stock (LU2557688560): latest FDA approval progress and biosimilar pipeline in focus - AD HOC NEWS
Alvotech shares rise as FDA completes Reykjavik facility inspection - MSN
Alvotech faces FDA setback for its Simponi biosimilar AVT05 - MSN
Alvotech (NasdaqGM:ALVO) Valuation Check After FDA Form 483 And Reaffirmed Approval Timelines - simplywall.st
Nordic Stocks Decrease; Alvotech Takes Biggest Hit - 富途牛牛
EBITDA of Alvotech Swedish Depository Receipt Repr 1 Sh – TURQUOISE:ALVOS - TradingView
Alvotech Plans June FDA Resubmissions, Sees Biosimilar Approvals by Year-End - MarketBeat
Transcript : Alvotech Presents at Bank of America Global Healthcare Conference 2026, May-13-2026 03 - marketscreener.com
Alvotech stock (LU2557688560): Partner Fuji Pharma reports valuation drop - AD HOC NEWS
Alvotech (ALVO) Q1 2026 Earnings Transcript - AOL.com
Alvotech (ALVO) Is Down 7.4% After FDA Form 483 on Key Site Inspection Has The Bull Case Changed? - Sahm
ALVO Stock Price, Quote & Chart | ALVOTECH SA (NASDAQ:ALVO) - ChartMill
Alvotech’s Iceland Manufacturing Facility Passes FDA Surveillance Inspection - geneonline.com
Alvotech Assured After FDA Facility Feedback - Citeline News & Insights
Alvotech Receives US FDA Observations Following Iceland Plant Inspection - Moomoo
Alvotech Clears Key FDA Inspection at Reykjavik Plant, Paving Way for 2026 BLA Resubmissions - TipRanks
Alvotech (NASDAQ: ALVO) reports FDA Form 483 but maintains 2026 BLA approval outlook - Stock Titan
Alvotech advances after FDA wraps Iceland plant inspection - MSN
Alvotech announces cGMP surveillance inspection of Reykjavik facility - TipRanks
FDA completes inspection at Alvotech's Reykjavik facility; company on track for BLA resubmissions this quarter - Pluang
Alvotech announces completion of FDA surveillance inspection at Reykjavik facility - The Manila Times
Alvotech Announces Completion of FDA Surveillance Inspection at Reykjavik Facility - The Manila Times
FDA issues Form 483 at Iceland plant; Alvotech still targets 2026 drug approvals - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
Alvotech reports completion of FDA inspection in Iceland - grafa.com
Alvotech stock (LU2557688560): Q1 2026 revenue dip and EBITDA rise on mix shift - AD HOC NEWS
Dr Reddy's Share Price: Hits ₹1,303.4 On June 5 After $29.5B Keytruda Biosimilar Deal With Alvotech (x8QfRltOd3) - Fathom Journal
Alvotech Earnings Call Balances Risk and Growth - The Globe and Mail
A Look At Alvotech (NasdaqGM:ALVO) Valuation After Weak Q1 2026 Results And Biosimilar Pipeline Updates - simplywall.st
ALVOW (Alvotech) warrants remain flat as quarterly earnings data not disclosed to markets.Current Ratio - newser.com
Nordic Shares Decline; Alvotech Posts Biggest Loss - Moomoo
Alvotech Q1 2026 slides: revenue dips 20%, EBITDA rises on mix shift - Investing.com Canada
Alvotech Q1 2026 slides: revenue dips 20%, EBITDA rises on mix shift By Investing.com - Investing.com South Africa
Earnings call transcript: Alvotech misses Q1 2026 earnings, stock dips - Investing.com UK
Alvotech’s Earnings Swing And Counsel Exit Might Change The Case For Investing In ALVO - Yahoo Finance
Alvotech (NASDAQ:ALVO) Shares Gap DownTime to Sell? - MarketBeat
Alvotech Q1 2026 Financial Results - Sahm
Earnings call transcript: Alvotech misses Q1 2026 earnings, stock dips By Investing.com - Investing.com South Africa
Alvotech Q1 Earnings Call Highlights - MarketBeat
Alvotech Stock (ALVO) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.92%
4.44%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):